Illumina, Inc. Overview
Pro stress-test →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications, generating over 90% of its revenue from sequencing instruments, consumables, and services. The company is a dominant player in DNA sequencing and genomic analysis, serving research institutions, hospitals, and pharmaceutical companies globally.
Strategic Profile
Pro stress-test →Management expects double-digit to mid-teens growth for the clinical business in 2026, while acknowledging ongoing challenges and muted growth in the research segment. In early February 2026, Illumina closed its SomaLogic acquisition, expanding into proteomics to build diversified multiomics capabilities.
Competitive Landscape
Pro stress-test →Bio-Rad Laboratories, Bio-Techne, Pacific BioSciences of California, QuidelOrtho, and Idexx Laboratories are among Illumina's 41 competitors. Illumina maintains market leadership in high-throughput sequencing but faces competition from specialized players in lower-throughput applications and emerging proteomics platforms.
Industry Context
Illumina, Inc. operates in Life Sciences Tools & Genomic Sequencing.
Key facts
Founded: 1998 · Headquarters: San Diego, US · Employees: ~7,500 · Revenue: $4.34B · Market cap: $20.4B